research use only

Miconazole Nitrate Fungal inhibitor

Cat.No.S1956

Miconazole (NSC 169434) Nitrate is an imidazole antifungal agent by inhibiting ergosterol biosynthesis and inducing ROS, used to treat vaginal yeast infections.
Jump to

Quality Control

Batch: Purity: 99.86%
99.86

Solubility

In vitro
Batch:

DMSO : 96 mg/mL (200.35 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 1 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 479.14 Formula

C18H14Cl4N2O.HNO3

Storage (From the date of receipt)
CAS No. 22832-87-7 Download SDF Storage of Stock Solutions

Synonyms NSC 169434 Nitrate SMILES C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-]

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro
Miconazole induces changes in the actin cytoskeleton, indicative of increased filament stability, prior to ROS induction. Miconazole disrupts steroidogenesis in Leydig and adrenal cells by inhibiting 17alpha-hydroxylase/17,20-lyase (P450c17) enzyme activity, thus reducing the conversion of progesterone to androstenedione. Miconazole reversibly inhibits (Bu)(2)cAMP-stimulated progesterone production in a dose- and time-dependent manner in MA-10 cells without affecting total protein synthesis or P450(scc) and 3beta-hydroxysteroid dehydrogenase (3beta-HSD) enzyme expression or activity. Miconazole is known to interfere with the synthesis of fungal and bacterial lipid membranes as it restrains the synthesis of Ergosterol which results in accumulation of toxic methylated sterol intermediates in membranes and subsequently in fungal cell growth arrests. Miconazole induces actin cytoskeleton stabilization in Saccharomyces cerevisiae prior to induction of reactive oxygen species, pointing to an ancillary mode of action. Miconazole treatment releases Ca(2+) from the thapsigargin (TG)-sensitive ER pool of WEHI7.2 cells. Miconazole induces apoptosis, based on morphological and biochemical criteria, and on inhibition by the Bcl-2 oncogene. Miconazole–induced intracellular Ca(2+) changes is inhibited by overexpression of Bcl-2. Miconazole induces apoptosis in the glucocorticoid sensitive and resistant human T-cell leukemia lines, CEM-C7 and CEM-C1 respectively, in normal thymocytes and in normal lymphocytes, in addition to inducing cell death in WEHI7.2 cells.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/19783660/
  • [5] https://pubmed.ncbi.nlm.nih.gov/17180102/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-12-31)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07311759 ACTIVE_NOT_RECRUITING
Chronic Paronychia
Cairo University
2024-08-17 PHASE3
NCT05916729 UNKNOWN
Oral Candidiases
University of Belgrade
2021-05-01 PHASE4
NCT05660382 COMPLETED
Otomycosis
Hill Dermaceuticals, Inc.
2023-03-02 PHASE3
NCT06214273 UNKNOWN
Chemotherapy Induced Oral Mucositis
Cairo University
2024-04 PHASE2
NCT04813822 UNKNOWN
Acute Vulvovaginal Candidiasis
Aesculape CRO Belgium BV
2021-09-13 PHASE2
NCT04432376 COMPLETED
Otomycosis
Hill Dermaceuticals, Inc.
2020-07-08 PHASE2; PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.